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Abstract
Background: Injection site infections among injecting drug users (IDUs) have been associated
with serious morbidity and health service costs in North America. This study explores the
frequency, factors and costs associated with injection site infections among IDUs in England.
Methods: Unlinked-anonymous survey during 2003/05 recruiting IDUs from community settings
at seven locations across England. Self-reported injecting practice, symptoms of injection site
infections (abscess or open wound) and health service utilisation data were collected using a
questionnaire, participants also provided dried blood spot samples (tested for markers blood borne
virus infections). Cost estimates were obtained by combining questionnaire data with information
from national databases and the scientific literature.
Results: 36% of the 1,058 participants reported an injection site infection in the last year. Those
reporting an injection site infection were more likely to be female and aged over 24, and to have:
injected into legs, groin, and hands in last year; injected on 14 or more days during the last four
weeks; cleaned needles/syringes for reuse; injected crack-cocaine; antibodies to hepatitis C; and
previously received prescribed substitute drug. Two-thirds of those with an injection site infection
reported seeking medical advice; half attended an emergency department and three-quarters of
these reported hospital admission. Simple conservative estimates of associated healthcare costs
range from £15.5 million per year to as high as £30 million; though if less conservative unit costs
assumptions are made the total may be much higher (£47 million). The vast majority of these costs
are due to hospital admissions and the uncertainty is due to little data on length of hospital stays.
Conclusion: Symptoms of injection site infections are common among IDUs in England. The
potential costs to the health service are substantial, but these costs need more accurate
determination. Better-targeted interventions to support safer injection need to be developed and
evaluated. The validity of self-reported symptoms, and the relationship between symptoms,
infection severity, and health seeking behaviour require further research.
Published: 18 September 2008
BMC Infectious Diseases 2008, 8:120 doi:10.1186/1471-2334-8-120
Received: 18 March 2008
Accepted: 18 September 2008
This article is available from: http://www.biomedcentral.com/1471-2334/8/120
© 2008 Hope et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
BMC Infectious Diseases 2008, 8:120 http://www.biomedcentral.com/1471-2334/8/120
Page 2 of 8
(page number not for citation purposes)
Background
A range of bacteria can infect injecting drug users' (IDUs)
injection sites, resulting in illnesses ranging from localised
skin and soft tissue infections to systemic and toxin pro-
ducing infections [1,2]. These infections can result in seri-
ous morbidity requiring inpatient intervention (e.g.
intensive intravenous antibiotics, surgical debridement,
amputation) and sometimes death [1,2]. The reported
prevalence of recent or current infections such as
abscesses, infected ulcers and cellulitus among IDUs
ranges from under one in 10 in Australia [3] to between
one in five and one in three in North America and Europe
[4-6]. These infections are also the most common present-
ing diagnoses among IDUs attending emergency depart-
ments in North America [7,8]. Injection site infections are
associated with poor hygiene and unsafe injection prac-
tices including inadequate cleaning of the hands or the
injection site, needle and syringe re-use, multiple injec-
tion attempts, use of multiple injection sites, subcutane-
ous injection, and drawing blood back into the syringe
repeatedly [3,5,9,10].
There has been increasing concern in the United Kingdom
(UK) about the extent of bacterial infections among IDUs
[11-13]. Reports of severe group A streptococci infections
among IDUs in the UK have increased over ten fold in
recent years from less than ten per annum in the mid
1990's to 143 per annum in 2004 [11]. There have also
been reports of community acquired Meticillin resistant
Staphylococcus aureus infection among IDUs in recent years
[14,15], and outbreaks of tetanus and wound botulism
[16,17].
Little is known about the extent of injection site infec-
tions, or the factors associated with them, among IDUs in
England. These infections are, however, likely to place a
considerable, and possibly increasing burden on health
services as observed elsewhere [3-5,18]. Using survey data,
this paper explores the prevalence and factors associated
with self-reported symptoms of injection site infections
(abscess or open wound), which are likely to be due to
bacterial infection, among IDUs in England, and explora-
tory cost estimates of their treatment.
Methods
Data on subject-reported symptoms of an injection site
bacterial infection, from a community-recruited survey of
IDUs undertaken in England was used [19]. Briefly, an
unlinked anonymous community-recruited survey was
undertaken between autumn 2003 and summer 2005.
This involved recruiting drug users who had injected dur-
ing the proceeding 28 days using established methods at
seven broadly representative locations across England.
Participants were recruited either directly from a range of
low threshold services, including drop-in centres and nee-
dle exchanges, or using indigenous fieldworkers to recruit
from the community settings[20]. Those who agreed to
take part, by providing verbal consent, were taken through
a detailed questionnaire on their demographic, behav-
ioural and drug use characteristics by trained interviewers.
They also provided dried blood spot samples for testing
for anti-bodies to hepatitis C (anti-HCV), hepatitis B core
antigen (anti-HBc), and HIV (anti-HIV), and were offered
a £10 acknowledgement. The questionnaire collected
information on self-reported symptoms of injecting site
infections, and use of health services in response to these.
The survey, part of the unlinked anonymous programme,
had multi-site approval from the London Research Ethics
Committee and from the relevant local committees.
Analyses
The symptoms of injection site infections considered were
reporting either an 'abscess (pus filled swelling)' or 'open
wound/sore' at an injection site, as these symptoms are
most likely to be due to a bacterial infection. All analyses
were undertaken in SPSS 14. Variables, such as demo-
graphic, drug use and behavioural characteristics, that
were found to be univariately associated with these symp-
toms using χ2, were then entered using the forward step-
wise procedure in SPSS in to a logistic regression model
with inclusion assessed using the likelihood ratio (with
the stepwise probability for inclusion of 0.05 and exclu-
sion of 0.1).
Cost estimation
The cost of treatment was estimated for those IDUs report-
ing having had an injection site infection in the last year
who also reported seeking medical advice. However, spe-
cific costs were not collected, and so the cost estimation
used standard UK costs from the National Health Service
(NHS) reference cost database for 2005–2006 [21] and
the 2006 review of 'Unit costs of Health and Social Care'
[22]. Also, only limited survey data were collected on
healthcare usage. Thus cost estimates were produced that
used lower and upper bound estimates for each unit cost
and assumed each IDU only had one injection site infec-
tion per year.
For those IDUs reporting that they attended an emergency
department, the lower and upper quartile costs of an 'Acci-
dent and Emergency lower cost investigation' (£67 or
£86) was applied [22]. For those who were then admitted
to hospital the survey did not collect data on the average
duration of hospital stay. Because of this, and because
there is little suitable published data on their likely length
of stay, two methods were used to produce estimates for
the costs of hospital care. The first method simply
assigned a low and high cost to each IDU's hospital stay
from the range in average unit costs for non-elective hos-
pital based acute care of skin infections (£944–1,556 per
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patient) [21]. Alternatively, cost projections were pro-
duced using the average daily NHS cost for hospital based
adult acute care for skin infections (£247–370 per day)
[21], and assuming a low and high estimate for the aver-
age number of days they stay in hospital (2 or 4 days)
[4,8,23]. However, because the cost per day is higher for
shorter hospital stays in the NHS cost database, the higher
daily cost was applied to the shorter length of stay and vice
versa for the longer length of stay. The estimates for an
IDU's length of stay were obtained from one Scottish
study and two US studies that looked at hospital admis-
sions of IDUs with soft tissue infections [4] or skin infec-
tions, abscesses and other health problems [8,23].
For those that sought medical advice but did not attend an
emergency department, it was assumed that they con-
sulted their general practitioner (GP). A low and high cost
was applied to this by using the upper and lower bound
cost for a GP surgery consultation (£18–25 per consulta-
tion) from Unit Costs of Health and Social Care [22].
The cost estimates for each care option were combined to
produce different cost estimates for the treatment of the
IDUs in the study. By multiplying the reported prevalence
of injection site infections in the last year with estimates
for the number of IDUs in England, 140,000 (only injec-
tors of opiates or crack-cocaine, low estimate) [24] or
215,000 (all IDUs, high estimate) [25], these treatment
costs were then scaled up to produce a range of estimates
for the yearly cost of treating IDUs with injection site
infections.
Results
This survey recruited 1,058 injectors from seven locations
in England: 77% (810/1,054) were male, 18% (193/
1,058) aged under 25 years (median age 30 years, range
16 to 72 years), 21% (221/1,056) had been injecting for
less than five years (median number of years injecting 9,
range < 1 to 41 years), and the prevalence of anti-HCV was
53% (566/1,058), anti-HBc was 32% (332/1,049), and
anti-HIV was 0.8% (8/1,058). Almost all had injected an
opiate in the previous four weeks (999/1,058), whilst
40% (424/1,058) had injected crack-cocaine and 13%
(136/1,058) an amphetamine. The majority (86%, 904/
1,056) had ever been homeless (having lived in a hostel,
being of no fixed abode, or living on the streets) and over
half (59%, 622/1,056) had last been homeless during the
proceeding 12 months.
Of the 1,058 participants, 385 (36%) reported having had
a symptom of an injection site infection (either an abscess
or open wound) in the previous year.
Factors associated with symptoms injection site infections
Reporting injection site infection in the previous year was
associated univariately with a range of factors (Table 1). In
the multivariate analysis (Table 1), a number of factors
remained associated with reporting an injection site infec-
tion: female gender; being aged 25 or over; having
injected into legs, groin, and hands in last year; injecting
on 14 or more days during the last 4 weeks, cleaning nee-
dles/syringes for reuse; injecting crack-cocaine; being anti-
HCV positive; and having previously received prescribed
substitute drug (i.e. not currently on prescribed opioid
substitute drug).
Factors associated with seeking health care for an injection 
site infection
Two thirds of those reporting an injection site infection
reported seeking health care (68%, 260/382). Seeking
health care among those having had injection site infec-
tion was associated univariately with the factors shown in
Table 2. In multivariate analyses (table 2), seeking health
care remained associated with two markers of healthcare
utilisation (currently being prescribed substitute drug,
and ever having had voluntary-confidential test for hepa-
titis C); a risk factor for infection (injecting into the
groin); and a marker of good hygiene practice (always
swabbing injection sites).
Heath services use and costs
Almost half of those seeking advice for an injection site
infection reported attending an emergency department
(47%, 180/381), with over three-quarters of those attend-
ing an emergency department reporting admission to hos-
pital (78%, 140/180). Estimates of the numbers of IDUs
accessing health services in England in relation to a con-
cern about an injection site infection are given in table 3.
These estimates indicate that over 30,000 IDUs are likely
to seek health care for injection site infections each year,
with at least 18,500 of them being admitted to hospital.
Assuming only a single episode per IDU each year, and
using conservative unit costs, the annual healthcare costs
associated with injection site infections among IDUs in
England are estimated to be at least £19.2 million for the
lower bound cost per hospital stay, and at least £30.5 mil-
lion for the upper bound cost per hospital stay (see table
4 for these estimates, both assuming an IDU population
of 140,000). This compares with a lower bound estimated
cost of at least £15.5 million when daily costs are used and
IDUs are assumed to stay in hospital for on average 2
days, and an upper bound cost of at least £20.6 million
when IDUs are assumed to stay on average 4 days (both
assuming an IDU population of 140,000). Irrespective of
the method used, the vast majority of these costs are due
to the periods of hospital admission, which makes up
over 88% of the total cost estimate.
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Table 1: Factors associated with an injection site infection in last year among injecting drug users: England 2003/05.
Yes N 
(Total = 990)
Univariate Odds 
Ratio with 95% 
confidence interval
Mulitvariate Adjusted  
Odds Ratio with 95% 
confidence interval
Gender Male 263 755 35% 1.0 1.0
Female 102 235 43% 1.4 1.1 – 1.9 1.7 1.2 – 2.4
Received prescribed substitute drug Currently 178 511 35% 1.0 1.0
Previously 150 322 47% 1.6 1.2 – 2.2 1.7 1.3 – 2.4
Never 37 157 24% 0.6 0.4 – 0.9 0.9 0.5 – 1.3
Age in Years <= 24 47 186 25% 1.0 1.0
25 – 29 103 273 38% 1.8 1.2 – 2.7 1.6 1.0 – 2.6
30 – 34 107 258 41% 2.1 1.4 – 3.2 2.0 1.3 – 3.2
35+ 108 273 40% 1.9 1.3 – 2.9 1.9 1.2 – 3.0
Inject into leg last 4 weeks No 212 701 30% 1.0 1.0
Yes 153 289 53% 2.6 2.0 – 3.4 2.2 1.6 – 3.1
Inject into groin last 4 weeks No 176 543 32% 1.0 1.0
Yes 189 447 42% 1.5 1.2 – 2.0 1.4 1.1 – 1.9
Inject into hand last 4 weeks No 245 759 32% 1.0 1.0
Yes 120 231 52% 2.3 1.7 – 3.1 1.9 1.3 – 2.6
Clean Needle/Syringe for reuse No 77 259 30% 1.0 1.0
Yes 288 731 39% 1.5 1.1 – 2.1 1.5 1.1 – 2.1
Inject crack last 4 weeks No 188 588 32% 1.0 1.0
Yes 177 402 44% 1.7 1.3 – 2.2 1.5 1.1 – 2.0
Days injected last 4 weeks <= 13 days 46 181 25% 1.0 1.0
14 – 27 days 84 208 40% 2.0 1.3 – 3.1 1.8 1.2 – 2.9
28 days 235 601 39% 1.9 1.3 – 2.7 1.5 1.0 – 2.3
Anti-HCV Positive No 135 454 30% 1.0 1.0
Yes 230 536 43% 1.8 1.4 – 2.3 1.5 1.1 – 2.0
Homeless Never 36 140 26% 1.0 †
Over a year ago 98 266 37% 1.7 1.1 – 2.7
In last year 231 584 40% 1.9 1.2 – 2.9
Number of years injecting <= 4 53 210 25% 1.0 †
5 – 9 120 300 40% 2.0 1.3 – 2.9
10 – 14 87 227 38% 1.8 1.2 – 2.8
15 + 105 253 42% 2.1 1.4 – 3.1
Inject into neck last 4 weeks No 288 841 34% 1.0 †
Yes 77 149 52% 2.1 1.4 – 2.9
Prepare drug using citric acid No 12 59 20% 1.0 †
Yes 353 931 38% 2.4 1.3 – 4.6
Times injected last full day Once 53 168 32% 1.0 †
Twice 77 266 29% 0.9 0.6 – 1.3
Thee times 81 203 40% 1.4 0.9 – 2.2
4+ times 154 353 44% 1.7 1.1 – 2.5
Clean injecting site last 4 weeks Never 185 444 42% 1.0 †
Sometimes 83 224 37% 0.8 0.6 – 1.1
Always 97 322 30% 0.6 0.4 – 0.8
Times injected with last needle Once 186 549 34% 1.0 †
Twice 68 189 36% 1.1 0.8 – 1.5
Three times 39 100 39% 1.2 0.8 – 1.9
4+ times 72 152 47% 1.8 1.2 – 2.5
Ever had voluntary confidential test for 
hepatitis C
Yes 257 652 39% 1.4 1.0 – 1.8 †
No 108 338 32% 1.0
Anti-HBc positive No 239 680 35% 1.0 †
Yes 126 310 41% 1.3 1.0 – 1.7
† Variable not in final model.
Note: Reporting an injection site infection in previous year was not associated with: having been imprisoned; having had an overdose; injecting 
amphetamines; washing hands before injection; injecting into arms; using vitamin c/ascorbic acid, lemon juice or vinegar to dissolve drugs; ever 
having had voluntary-confidential test for HIV; and uptake of hepatitis B vaccine.
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Table 2: Factors associated with healthcare seeking among injecting drug users reporting an injection site infection in past year: 
England 2003/05.
Yes N 
(Total = 365)
Univariate Odds  
Ratio with 95% 
confidence interval
Mulitvariate Adjusted 
Odds Ratio with 95% 
confidence interval
Received prescribed substitute drug Currently 138 182 76% 1.0 1.0
Previously 94 147 64% 0.6 0.4 – 0.9 0.5 0.3 – 0.9
Never 15 36 42% 0.2 0.1 – 0.5 0.3 0.1 – 0.7
Inject into groin last 4 weeks No 100 174 57% 1.0 1.0
Yes 147 191 77% 2.5 1.6 – 3.9 2.1 1.3 – 3.4
Clean injecting site last 4 weeks Never 113 184 61% 1.0 1.0
Sometimes 58 85 68% 1.3 0.8 – 2.3 1.4 0.8 – 2.6
Always 76 96 79% 2.4 1.3 – 4.2 2.5 1.4 – 4.6
Ever had voluntary confidential test for hepatitis 
C
Yes 195 257 76% 3.4 2.1 – 5.4 3.5 2.1 – 5.8
No 52 108 48% 1.0 1.0
Number of years injecting <= 4 25 53 47% 1.0 †
5 – 9 80 120 67% 2.2 1.2 – 4.3
10 – 14 64 84 76% 3.6 1.7 – 7.5
15 + 78 108 72% 2.9 1.5 – 5.8
Inject into arm last 4 weeks No 72 94 77% 1.0 †
Yes 175 271 65% 0.6 0.3 – 1.0
Ever had voluntary confidential test for HIV No 71 132 54% 1.0 †
Yes 176 233 76% 2.7 1.7 – 4.2
Anti-HCV Positive No 80 134 60% 1.0 †
Yes 167 231 72% 1.8 1.1 – 2.8
† Variable not in final model.
Note: Seeking health care an injection site infection was found not to be associated with: gender; age; homelessness; having been imprisoned; having 
had an overdose; cleaning needles and syringes before reuse; injecting crack-cocaine; injecting amphetamines; number of days injecting per month; 
number times inject per day; using citric acid, vitamin c/ascorbic acid, lemon juice, or vinegar to dissolve drugs; injecting into legs, neck or hands; 
number times used last needle; washing hands before injection; and uptake of hepatitis B vaccine.
Table 3: Estimated annual numbers of injecting drug users in England seeking healthcare for injection site infections.
Proportion of survey 
respondents
Estimated number of IDUs in 
England: 140,000 *
Estimated number of IDUs in 
England: 215,000 **
IDUs reporting abscess/open 
wound in last year
36% 50,400 77,400
Those IDUs reporting abscess/
open wound in last year 
seeking care:
24% 34,272 52,632
Of these, those that sought 
care:
other than at an 
Emergency Department
8% 10,584 16,254
at an Emergency 
Department, not admitted 
to hospital
4% 5,211 8,003
at an Emergency 
Department, & admitted 
to hospital
13% 18,477 28,375
* Estimated number of injectors of heroin or crack-cocaine only, form a study aiming to estimate the total number of heroin and crack-cocaine 
users [24].
** Estimated number of injecting drug users (all drugs) obtained from a study using an evidence synthesis method to estimate number of injecting 
drug users [25].
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Discussion
Symptoms of injection site infections appear to be com-
mon amongst IDUs in England. These infections are asso-
ciated with reuse of syringes, particular injection sites,
crack injecting, having hepatitis C infection and being
female; with one in seven of the IDUs reporting hospital
admission annually. These infections are preventable, yet
based on conservative exploratory estimates they may cost
the health service in England at least £15.5–19.2 million
per annum.
The high prevalence of self-reported injection site infec-
tions found in this study, as found elsewhere [4,5], are of
concern and highlight the need for interventions which
facilitate good injection related hygiene and practice.
Firstly, this study found that the injection sites used and
the reuse of injecting equipment were associated with
injection site infections. Previous studies have found sim-
ilar associations [9,10]; and also associations with inade-
quate washing of hands or cleaning of the injection site
[5,9,10]; multiple injection attempts before locating a
vein, and the use of multiple injection sites [9,10]. The
association with femoral ('groin') injection is of particular
concern as this has become more common in recent years
[26], with indications of increased hospital admissions
related to femoral injection among IDUs [13].
Participants injecting crack-cocaine also reported higher
levels of injection site infections, as has been observed
elsewhere with the injection of cocaine [6,8,36], and her-
oin and cocaine combinations [10,27]. There is also evi-
dence to suggest crack-cocaine use, which is associated
with risky behaviours [26,28], has become more common
in the UK [29]. As in other studies, women were more
likely to report an injection site infection [6,10,27]. This
may reflect a higher awareness of infections, and/or a
greater vulnerability to injection site infections among
female injectors[30]. The positive association with previ-
ously receiving a prescribed substitute drug suggests that
those factors leading to people not successfully complet-
ing treatment for their drug use may also put them at ele-
vated risk of infection, though this needs further
examination.
In this study homelessness – a possible marker for injec-
tion in public places – was not associated with injection
site infections in the final analyses. This may reflect the
relatively broad definition used. In previous studies pub-
lic or semi-public injecting environments have been
related to poor injection hygiene and infections [9,10,31].
In the UK there is increasing concern about public injec-
tion and its impact on injecting hygiene [26,28]. Preven-
tive interventions should thus focus on the reuse of
injecting equipment, and target those injecting into
groins, legs or hand, using crack-cocaine, and female
injectors; they may also need to consider the role of the
injecting environment [32].
The conservative cost estimate from this study – at least
£15.5–19.5 million per annum – indicates that injecting
site infections could place a considerable cost burden on
the health care system in England. Previous work looking
at the costs of problematic drug use, both injecting and
non-injecting, in England indicated considerable health
care costs of around £500 million per annum [33]. Whilst
£25 million of this was estimated to be due to blood
borne viruses (HIV, hepatitis B and C) among IDUs, the
authors did not separate the costs related to injecting
Table 4: Estimated annual costs for injecting drug users (IDUs) in England seeking healthcare for injection site infections.
Estimated costs in 1,000 pounds sterling (£)
Low unit costs† High unit costs†
Estimated number of IDUs in England 140,000* 215,000** 140,000* 215,000**
Estimated cost of GP consultations 191 293 265 406
Estimated cost of A&E visits 1,587 2,437 2,037 3,129
Estimated cost of hospital bed days 17,442 26,786 28,750 44,151
Total 19,220 29,516 30,527 46,881
* Low estimate of number of IDUs is the number of heroin or crack-cocaine injectors, form a study aiming to estimate the total number of heroin 
and crack-cocaine users [24].
** High estimate of number of IDUs is the estimated number of IDUs (all drugs) obtained from a study using an evidence synthesis method to 
estimate number of injecting drug users [25].
† Low and High Unit costs based on Unit Costs of Health and Social Care 2006 [22] and NHS cost database [21]. Unit cost GP consultation: Low 
£18 & High £25 [22]. Average Unit cost for a lower cost investigation at Accident and Emergency (Emergency Department): Low £67, & High £86 
[22,21]. Average Unit costs per hospital stay were based on the low and high average cost for non-elective adult acute care in a hospital for a skin 
infection from NHS cost database [21], Alternative estimates are produced using daily unit costs and assuming they stay in hospital for 2 or 4 days 
[4,8,23]
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users. They were also not able to separate out the costs
related to injecting site infections, and these may not have
been fully accounted for in their estimate.
Most of the participants reporting an injection site infec-
tion sought medical advice and one third of those with an
infection reported being admitted to hospital, many via
an emergency department. This is consistent with other
studies which suggest that IDUs tend not to seek timely
medical care for their injecting-related health problems,
often resulting in emergency treatment at considerable
cost [8,18,34,35]. The failure to seek earlier treatment
probably reflects competing priorities, such as, obtaining
money, purchasing and using drugs, barriers to accessing
care, and poor compliance with oral antibiotic regimes
and follow-up care [8,18,35,36]. Emergency room use
(8% of total cost) and hospital admission (> 90% of total
cost) account for much of the estimated costs. These costs
could be reduced substantially, past studies have shown
that earlier health care seeking and targeted prevention
can reduce emergency department visits, hospital bed
days, and surgical procedures by more than a third
[37,38]. Whilst further work needs to identify, develop,
and evaluate suitable interventions, our findings suggest a
need to focus on improving injection hygiene, the better
management of the body sites used for injection, and that
IDUs are possibly more likely to seek care if in contact
with other services.
It is important to consider the limitations and generalisa-
bility of these findings. Self-reported symptoms of inject-
ing site infections were used in this study; however,
studies have shown good concordance between self-
reported symptoms and clinical diagnosis [18]. The com-
parative rarity, marginalisation and illegal nature of
injecting drug use impedes the recruitment of a represent-
ative sample of injectors. This study aimed to minimise
sampling biases and maximise representativeness by
using an established community sampling strategy [20].
However, in particular, bias might arise from high-risk
individuals being more likely to be captured in the survey
as a result of them making greater use of the needle
exchanges, and other settings, where sampling occurred.
As a consequence the cost estimates could be over esti-
mates. The cost estimates were however calculated con-
servatively. Firstly, they assume that IDUs seeking care
only did so once each year – yet some will have more than
one such episode of care per annum and a Canadian study
found that half of IDUs admitted to hospital for soft-tis-
sue and systemic infections had multiple admissions [8].
If this was the case then the estimated costs of injection
site infections in England could be more than 50%
greater, or at least £23 million per annum. Four days for a
long hospital stay may also be conservative, as those with
a serious systemic infection could stay much longer, as has
found in hospitals in the USA (3 to 13 days) [4,34,39].
However, the available data on length of IDU hospital
stays is limited, with the only UK data being 20 years old
and no clinical data were collected as part of this study.
The cost estimates also excluded any periods of care in
high dependency units, or other high cost services, which
may be required for treatment of the more severe infec-
tions. Even so, the costing, and other findings, presented
here are tentative, and a more rigorous economic evalua-
tion is required that includes UK specific data on the aver-
age hospital stay for IDUs with infection site infections
and the costs of these.
Conclusion
Taken together these findings suggest injection site infec-
tions are common experiences among IDUs in England,
and that the resultant health care costs are likely to be sub-
stantial. However, the size of these costs needs to be more
fully determined. Further research is also needed to
explore issues around the validity of self-reports and the
relationship between these reported symptoms of infec-
tion, the severity of the infection, and health seeking
behaviour.
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